Inosine

Product Details

CAS No:58-63-9

MF:C10H12N4O5

Appearance:white or off-white crystalline powder

Specification:98.5%

UN number:-

Package:1/5/10/25kgs/drum

Supply Capacity:MT

Synonyms:Atorel;beta-D-Ribofuranoside, hypoxanthine-9;Hypoxanthine D-riboside;Hypoxanthine, 9-beta-D-ribofuranosyl-;hypoxanthined-riboside;hypoxanthinenucleoside;Ino;INO 495; inosine; 58-63-9; Hypoxanthosine; Ribonosine; Atorel; Oxiamin; Hypoxanthine riboside; Trophicardyl; Selfer; Hypoxanthine D-riboside; 9-beta-D-Ribofuranosylhypoxanthine; Hypoxanthine ribonucleoside; Hypoxanthine nucleoside; Inosina; Inosinum; Inotin; INO 495; DTXSID2045993; 5A614L51CT; NSC-20262; 9-beta-D-ribofuranosyl-9H-purin-6-ol; DTXCID0025993; CHEBI:17596; 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one; 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-1H-purin-6-one; 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-3H-purin-6-one; 9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-1H-purin-6-one; 9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-6,9-dihydro-1H-purin-6-one; 9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-6,9-dihydro-3H-purin-6-one; RefChem:791048; D06BB05; G01AX02; S01XA10; 9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-3H-purin-6-one; 200-390-4; Panholic-L; Pantholic-L; (-)-Inosine; Inosie; iso-prinosine; Inosine [INN:JAN]; Inosinum [INN-Latin]; Inosina [INN-Spanish]; hypoxanthine-ribose; INO; MFCD00066770; Hypoxanthine, 9-beta-D-ribofuranosyl-; Inosin; AI3-52241; HXR; Hypoxanthine-9-beta-D-ribofuranoside; NSC 20262; beta-D-Ribofuranoside, hypoxanthine-9; Hypoxanthine 9-beta-D-ribofuranoside; MLS000028518; 9.beta.-D-Ribofuranosylhypoxanthine; 1,9-Dihydro-9-beta-D-ribofuranosyl-6H-purin-6-one; 9-.beta.-D-Ribofuranosylhypoxanthine; SMR000058316; 9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-purin-6(9H)-one; .beta.-Inosine; 9-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3H-purin-6(9H)-one; CAS-58-63-9; SR-01000721862; EINECS 200-390-4; Carnine; Catacol; Hypoxanthosine;; NSC20262; Trophicardyl;; UNII-5A614L51CT; Oxiamine;; 3h-inosine; D-Inosine; Inosie;; 2ada; 2fqw; .beta.-D-Ribofuranoside, hypoxanthine-9; NCGC00095787-01; Adenosine Imp. G (EP); Inosine; Didanosine Imp. B (Ph. Int.); 9-beta-D-Ribofuranosyl-1,9-dihydro-6H-purin-6-one; Adenosine Impurity G; Didanosine Impurity B; Hypoxanthine, 9-.beta.-D-ribofuranosyl-; Inotin (TN); Hypoxanthine riboside;; CID 5274258; Inosine (JAN/INN); 1a4m; Inosine (8CI,9CI); INOSINE [INN]; INOSINE [JAN]; INOSINE [MI]; INOSINE [MART.]; Opera_ID_1628; INOSINE [WHO-DD]; INOSINE [WHO-IP]; bmse000098; bmse000888; bmse000978; cid_6021; CHEMBL1556; SCHEMBL15804; KBioGR_002560; KBioSS_002569; INOSINE [USP IMPURITY]; GTPL4554; orb1224575; orb1310617; orb3025449; SCHEMBL1682742; SCHEMBL3365586; SCHEMBL6933022; 9-b-D-Ribofuranosylhypoxanthine; Hypoxanthine-9-D-ribofuranoside; Inosine, >=99% (HPLC); SCHEMBL18653532; 9beta-D-Ribofuranosylhypoxanthine; BDBM22104; KBio2_002560; KBio2_005128; KBio2_007696; KBio3_003038; 9-|A-D-Ribofuranosylhypoxanthine; 9-b-D-ribofuranosyl-Hypoxanthine; MSK6812; 9-|_-D-Ribofuranosylhypoxanthine; cMAP_000084; HMS2235I17; Hypoxanthine-9-delta-ribofuranoside; 9-beta-D-ribofuranosyl-Hypoxanthine; HY-N0092; 9beta-delta-Ribofuranosylhypoxanthine; Tox21_111522; BDBM50366815; beta-D-Ribofuranoside hypoxanthine-9; EBC-44242; EBC-47437; hypoxanthine-9 beta-D-Ribofuranoside; 9-beta-delta-Ribofuranosylhypoxanthine; (2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-hydroxypurin-9-yl)oxolane-3,4-diol; AKOS015969695; AKOS015995607; AKOS024462561; Atorel; HXR; Hypoxanthine D-riboside; Tox21_111522_1; 9-beta-delta-ribofuranosyl-Hypoxanthine; CCG-267127; CS-5845; DB04335; DIDANOSINE IMPURITY B [WHO-IP]; NI06297; 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-3H-purin-6-one; beta-delta-Ribofuranoside hypoxanthine-9; Hypoxanthine 9-beta-delta-ribofuranoside; hypoxanthine-9 beta-delta-Ribofuranoside; Hypoxanthine-9-beta-delta-ribofuranoside; SMP1_000165; NCGC00095787-05; NCGC00095787-06; NCGC00096119-02; NCGC00096119-03; AS-11754; BP-51105; SY005000; 9-(beta-D-ribofuranosyl)-9H-purin-6-ol; ADENOSINE IMPURITY G [EP IMPURITY]; DB-029916; DIDANOSINE IMPURITY B [EP IMPURITY]; I0037; NS00010210; C00294; D00054; EN300-310328; (?)-Inosine; Hypoxanthine 9-|A-D-ribofuranoside; 1,9-dihydro-9-b-D-ribofuranosyl-6H-Purin-6-one; I538583; Q422564; SR-01000721862-2; SR-01000721862-3; AC89F8E4-FD89-45EE-8B41-94DFC07AB42F; BRD-K79612754-001-19-1; BRD-K79612754-001-21-7; 1,9-Dihydro-9-beta-delta-ribofuranosyl-6H-purin-6-one; 6H-Purin-6-one, 1,9-dihydro-9-beta-D-ribofuranosyl-; Z2681890654; Inosine; Adenosine EP Impurity G; Didanosine EP Impurity B; 9-.BETA.-D-RIBOFURANOSYL-1,9-DIHYDRO-6H-PURIN-6-ONE; 9-beta-D-Ribofuranosyl-1,9-dihydro-6H-purin-6-one (Inosine); Inosine; Adenosine EP Impurity G;
Didanosine EP Impurity B; 9-.BETA.-D-RIBOFURANOSYL-1,9-DIHYDRO-6H-PURIN-6-ONE [WHO-IP]; (2R,3R,4S,5R)-2-(6-hydroxy-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-hydroxy-9H-purin-9-yl)tetrahydrofuran-3,4-diol; 9-(3,4-DIHYDROXY-5-HYDROXYMETHYL-TETRAHYDRO-FURAN-2-YL)-1,9-DIHYDRO-PURIN-6-ONE; 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-purin-6-one; 478182-32-0; 9-|A-D-Ribofuranosylhypoxanthine; 9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,9-dihydro-6H-purin-6-one; InChI=1/C10H12N4O5/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18/h2-4,6-7,10,15-17H,1H2,(H,11,12,18)/t4-,6-,7-,10-/m1/s

Product application:Inosine,58-63-9,Hypoxanthine riboside,Hypoxanthosine,9-beta-D-Ribofuranosylhypoxanthine,Natural purine nucleoside,Pharmaceutical grade Inosine,USP grade inosine,EP grade inosine,Injectable inosine API,Hepatoprotective agent raw material,Leukopenia therapeutic active,Myocardial metabolism enhancer,Retinal neuroprotection nutrient,Sports nutrition endurance active,ATP synthesis precursor,Cellular energy activator,Immunomodulatory nucleoside,Food grade inosine,Cell culture medium component,Biofermentation nutrient,High purity Inosine 99%,Inosine manufacturer China,CAS 58-63-9 supplier,Suzhou Health Chemicals nucleosides,Inosine wholesale bulk export

 

Inosine serves as an indispensable natural purine nucleoside, vital metabolic energy precursor, and versatile active pharmaceutical ingredient extensively utilized across clinical therapeutics, cardiovascular medicine, sports nutrition, and bioprocess engineering. In commercial pharmaceutical manufacturing and clinical therapeutics, functioning as an essential intermediate in intracellular adenine nucleotide synthesis, it directly penetrates cellular membranes to stimulate ATP and Coenzyme A regeneration under ischemic or hypoxic microenvironments; it is universally formulated into oral tablets, syrups, and sterile injectable solutions to support liver function recovery, mitigate transaminase elevation in chronic hepatitis and cirrhosis, stimulate bone marrow granulopoiesis to counter radiation- or chemotherapy-induced leukopenia, and provide neuroprotective support in retinal atrophy and optic nerve pathologies. In athletic sports nutrition and dietary functional formulations, Inosine is widely utilized as an ergogenic active to optimize 2,3-diphosphoglycerate levels in erythrocytes, thereby enhancing muscular oxygen extraction efficiency, boosting anaerobic endurance capacity, and attenuating physical exhaustion during high-intensity training. Furthermore, in upstream biopharmaceutical processing and cell biology, Inosine is a foundational nucleoside supplement in serum-free mammalian cell culture media to maintain cell viability and enhance recombinant protein expression in biomanufacturing bioreactors.